CeriBell (NASDAQ:CBLL) Share Price Breaks Above Fifty Day Moving Average – Should You Sell?

CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) shares passed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $25.66 and traded as high as $26.00. CeriBell shares last traded at $25.75, with a volume of 537,237 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on CBLL shares. TD Cowen raised their price target on CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, October 2nd. Canaccord Genuity Group increased their price objective on CeriBell from $26.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. BTIG Research reissued a “buy” rating on shares of CeriBell in a report on Wednesday, November 4th. Finally, Barclays raised shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, CeriBell presently has an average rating of “Moderate Buy” and a consensus price target of $31.25.

Check Out Our Latest Report on CeriBell

CeriBell Price Performance

The firm has a market cap of $1.00 billion, a PE ratio of -13.27 and a beta of 0.86. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.18 and a quick ratio of 7.79. The firm has a 50-day simple moving average of $25.66 and a 200 day simple moving average of $21.15.

CeriBell (NASDAQ:CBLL – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. The company had revenue of $29.34 million during the quarter, compared to the consensus estimate of $29.18 million. As a group, equities analysts expect that CeriBell, Inc. will post -2.05 EPS for the current year.

Insider Activity

In related news, Director Joseph Taylor sold 10,200 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $27.22, for a total value of $277,644.00. Following the completion of the transaction, the director directly owned 38,278 shares in the company, valued at $1,041,927.16. The trade was a 21.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Xingjuan Chao sold 20,846 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $25.03, for a total value of $521,775.38. Following the completion of the transaction, the chief executive officer directly owned 746,345 shares in the company, valued at $18,681,015.35. This trade represents a 2.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 139,859 shares of company stock valued at $3,554,775. Company insiders own 17.70% of the company’s stock.

Hedge Funds Weigh In On CeriBell

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of CeriBell during the 2nd quarter valued at about $37,657,000. Bank of New York Mellon Corp bought a new position in CeriBell during the second quarter valued at approximately $17,437,000. TimesSquare Capital Management LLC bought a new position in CeriBell during the second quarter valued at approximately $15,182,000. KCM Capital Inc boosted its holdings in CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after purchasing an additional 400,000 shares during the last quarter. Finally, Bank of America Corp DE purchased a new stake in CeriBell in the second quarter worth approximately $4,619,000.

CeriBell Company Profile

(Get Free Report)

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.

Featured Articles

Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.